Christine Cotton Preservation archive
English Français

Interviews & video appearances

A searchable catalog of her 18 video interviews on YouTube and Dailymotion. Most are in French. Transcripts have not yet been generated; the link on each card takes you to the original video.

YouTube
Le désastre sanitaire ne fait que commencer I Christine Cotton
Cercle Aristote - Pierre Yves Rougeyron
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2024-02-01🎙️ Pierre-Yves Rougeyron📺 Cercle Aristote⏱ 40 min
“It was known there was no effect on severe cases in December 2020. It was known there was no effect on those over 75. It is written in the reports.”

Key statements

  • Transmission was never studied in the registration trial. ▶ 03:57
    Sources: Pfizer C4591001 Protocol
  • Results were provided after only a three-month interim follow-up, even though the trial was designed to last two years. Safety beyond three months therefore could not be asserted. ▶ 04:01
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • From December 2020 onward, the Pfizer trial's primary endpoint counted only mild and moderate PCR-confirmed COVID cases, measured 7 days after dose 2. Had cases been counted by anti-nucleocapsid serology, efficacy would have been roughly 50%, not 95%. ▶ 04:25
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • The December 2020 report shows no demonstrated effect on severe cases and no demonstrated effect on participants over 75 years of age. "It is written in the reports." ▶ 04:55
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • The same flawed methodology was reused without adjustment for the 11-15, 5-11, and 6-month-to-4-year trials, including authorization of 3-4 doses in infants whose COVID mortality risk is extremely low. ▶ 05:45
    Sources: Pfizer pediatric trial reports (12-15 yrs, 5-11 yrs, 6 months-4 yrs)
  • ICH Good Clinical Practice standards — the same standards her CRO was repeatedly audited against by Ipsen and the FDA — are not respected in the COVID trials. ▶ 06:55
    Sources: ICH-GCP guidelines
  • The leaked Pfizer-South Africa contract (signed April 2021) declared the Phase 2-3 clinical trials "completed" — impossible, since the protocol called for two years of follow-up. If the underlying results are false, the liability shield in those contracts may be void. ▶ 09:21
    Sources: Leaked Pfizer-South Africa supply contract (April 2021)
  • The vaccine administered to the public is not the vaccine of the clinical trial: the manufacturing chain (Process 2) was changed, with the new process tested per protocol on only 250 patients per batch. mRNA integrity of the rolled-out product is lower than in the trial product, and independent vial analyses show DNA impurities. ▶ 13:31
    Sources: Pfizer C4591001 Protocol (Process 2 amendment); Pfizer C4591001 trial database (FOIA / court-released)
  • The December 2020 EU Risk Management Plan formally records gaps for pregnant women, immunocompromised patients, and co-administration with other vaccines (no interaction study) — at the moment of authorization. ▶ 16:30
    Sources: Comirnaty Risk Management Plan (Dec 2020, EMA)
  • A Moderna SEC filing acknowledges these products are gene therapies that were classified as vaccines to accelerate development — bypassing the additional animal and human testing a gene therapy would have required. ▶ 22:44
    Sources: Moderna SEC 10-K / S-1 filing (gene-therapy classification)
  • At an FDA / CDC public meeting on 22 October 2020, regulators presented a long list of adverse events to actively monitor: Guillain-Barré, transverse myelitis, encephalitis, myocarditis/pericarditis, anaphylaxis, stroke, thrombocytopenia, disseminated intravascular coagulation, autoimmune disease, and more. The harms were anticipated before rollout. ▶ 26:31
    Sources: FDA VRBPAC meeting (22 Oct 2020) — adverse events of special interest slide deck
  • Trial participants who suffered serious adverse events were ignored: Brian Dressen (AstraZeneca), Augusto Roux (Pfizer adult arm, Argentina, nearly died), Maddie de Garay (Pfizer adolescent arm, 35 serious adverse events, testified to Senator Ron Johnson). ▶ 31:16
    Sources: Augusto Roux medical file; Maddie de Garay testimony to Sen. Ron Johnson
  • After Cotton posted her January 2022 report to LinkedIn, the post was visited (in two days, before LinkedIn closed her account) by 133 lawyers and by people from the US State Department, French National Gendarmerie, Ministry of the Armed Forces, Ministry of the Interior, Apple, the WHO, Thales, Airbus, and various state agencies. ▶ 32:43
    Sources: Cotton — January 2022 expertise report (LinkedIn post)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Comirnaty EU Risk Management Plan (December 2020) — EMA EPAR archive
  • Pfizer C4591001 trial database (court-released) — Court orders following FOIA / PHMPT litigation
  • Leaked Pfizer-South Africa supply contract (April 2021) — Health Justice Initiative (S. Africa) disclosure
  • Moderna SEC filing referencing gene-therapy classification — SEC EDGAR
  • FDA VRBPAC meeting (22 October 2020) — adverse-event monitoring slides — FDA / CDC public materials, available on the FDA YouTube channel
  • Christine Cotton — Expertise report (January 2022 version) — christinecotton.com
  • Andrew Bridgen — UK Parliament speech on excess mortality (Dec 2023) — Hansard
YouTube
Covid : où en sont les chiffres en 2023 ?
Sud Radio
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-09-27🎙️ André Bercoff (host)📺 Sud Radio⏱ 20 min
“We've been taken for fools from the start. The 95% only covered mild and moderate PCR-confirmed cases counted from 7 days after dose 2 — it never concerned everyone.”

Key statements

  • The 95% efficacy figure announced in December 2020 covered only mild and moderate PCR-confirmed COVID cases counted from 7 days after dose 2 — not asymptomatic cases, not excluded populations such as pregnant women, not patients with comorbidities. ▶ 05:46
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • In December 2020 there was no proven efficacy on severe cases. Cotton repeats that antibodies were not measured, in her view deliberately, to avoid showing they were declining. ▶ 06:16
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Transmission was not studied in the trial. All of this could be known from the clinical-trial protocol from October 2020 onward — health agencies have known since the beginning because they hold the protocols. ▶ 06:52
    Sources: Pfizer C4591001 Protocol
  • The leaked Pfizer-South Africa contract (signed April 2021) declares that the product had "completed" Phase 2-3 clinical trials. This is impossible: the Phase 3 trial began in July 2020 and was designed to last two years, so it could not have been completed by April 2021. ▶ 07:39
    Sources: Leaked Pfizer-South Africa supply contract (April 2021)
  • By April 2021 the adolescent (12-15) clinical study report stated in black and white, on page 38, that the unknowns for adolescents were the same as for adults: duration of protection, efficacy in at-risk subgroups, efficacy on symptomatic cases, long-term effects, mortality, and transmission — all unknown. ▶ 08:19
    Sources: Pfizer C4591001 adolescent (12-15) clinical study report (April 2021)
  • Results were released after a maximum of three months of follow-up, with 50% of participants followed for less than two months — yet authorizations were granted in December 2020 for elderly and immunocompromised people who had no demonstrated efficacy in the clinical report. ▶ 09:44
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • The Haute Autorité de Santé still recommends co-administering the Pfizer vaccine with the flu vaccine despite there being no clinical trial — no interaction study has ever been performed. ▶ 11:14
    Sources: Comirnaty Risk Management Plan (EMA)
  • At the moment the Pfizer vaccine was authorized with its 95% headline, the manufacturing chain had just been changed (Process 2). The product administered to the public is not the product of the clinical trial. The EMA had voiced major reservations because the integral mRNA content of the commercial product was lower than in the trial product. ▶ 12:11
    Sources: Pfizer C4591001 Protocol (Process 2 amendment); EMA assessment report (Comirnaty)
  • EudraVigilance (EMA) shows 1.2 million reported cases for the first monovalent Pfizer vaccine alone, with 25% serious. With a conservative 10-fold under-reporting factor, that would mean 12 million sick people in Europe. Cotton cites a 2006 publication co-signed by a French pharmacovigilance leader estimating under-reporting could require multiplying some serious cases by 100. ▶ 16:51
    Sources: EudraVigilance (EMA adverse-event database); 2006 French pharmacovigilance publication (Jean-Ville Bérat et al.)
  • Documented risks were known and included in the Risk Management Plan: initially anaphylaxis (later removed), myocarditis/pericarditis, and disease enhancement where the vaccine fatigues the immune system instead of protecting. Cotton asks where the favorable benefit/risk ratio could possibly be found — "On the Moon? Certainly not on Earth." ▶ 17:51
    Sources: Comirnaty Risk Management Plan (EMA)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 adolescent (12-15) clinical study report (April 2021) — EMA / FDA submissions (court-released)
  • Leaked Pfizer-South Africa supply contract (April 2021) — Health Justice Initiative (S. Africa) disclosure
  • EMA assessment report (Comirnaty) — Process 2 mRNA integrity reservations — EMA EPAR archive
  • EudraVigilance (EMA) — adverse-event database — adrreports.eu
  • 2006 French pharmacovigilance under-reporting publication (Jean-Ville Bérat et al.) — Peer-reviewed pharmacology journal
  • ANSM February 2023 vaccine efficacy update (45% / 56% / 75% figures cited by host) — ansm.sante.fr
YouTube
La vérité sur les essais Pfizer - Le Zoom - Christine Cotton - TVL
Chaîne officielle TVL
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-10-11🎙️ Élise Blaise (TVL host)📺 TVL (TV Libertés) — Le Zoom⏱ 33 min
“I've never in my life as a biostatistician — since 1995 — seen a trial with methodology of this mediocrity. Never.”

Key statements

  • The South Africa Pfizer contract shows the state assuming the risk of ordering a product whose long-term tolerability and efficacy were not really known. ▶ 00:48
    Sources: Leaked Pfizer-South Africa supply contract (April 2021)
  • Page 8 of the South Africa contract states the product had "completed" Phase 2-3 clinical trials. This is impossible: the trial began July 2020 and was scheduled to run for two years. The April 2021 adolescent clinical study report listed all the key information as still missing — transmission, mortality, symptomatic cases, long-term protection and tolerability. ▶ 01:22
    Sources: Leaked Pfizer-South Africa supply contract (April 2021); Pfizer C4591001 adolescent (12-15) clinical study report (April 2021)
  • The European Commission's contract with Pfizer has not been seen by the public. MEPs were apparently shown it but were not allowed to keep a copy — "a vast masquerade," with redacted passages and (Cotton jokes) maybe even an electronic signature alongside the von der Leyen-Bourla SMS. ▶ 02:30
    Sources: EU Advance Purchase Agreements (Pfizer/BioNTech)
  • Since 1995 Cotton has never worked with anyone but competent professionals respecting Good Clinical Practice. A biostatistician is by definition incorruptible: they sign the clinical report and engage their responsibility on the results. ▶ 03:06
    Sources: ICH-GCP guidelines
  • Pfizer began Phase 1 in April 2020, Phase 3 in July 2020, recruited about 44,000 participants and reported in November 2020 with the famous 95% efficacy — measuring only mild and moderate PCR-confirmed COVID cases counted from 7 days after dose 2. ▶ 07:03
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • Phase boundaries were not respected: Phase 2 began before Phase 1 was finished; Phase 3 began before Phase 2 was finished; the interim analysis was done after only three months of follow-up, with 50% of participants (about 18,000 people) followed for less than two months. Cotton: "Is that enough hindsight for tolerability?" ▶ 08:45
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • The FDA gave Pfizer "a freeway" by changing the vaccine analysis guidelines to allow results after only three months of follow-up — unprecedented. Cotton asks why three months and not four: "Maybe at four months they would have measured the antibodies, and seen that they only last four months — so the vaccine couldn't be approved." ▶ 11:06
    Sources: FDA Guidance on Development and Licensure of Vaccines to Prevent COVID-19 (June 2020)
  • The pre-clinical monkey publication already showed antibodies rising and then falling. Olivier Véran's predecessor Jérôme Salomon publicly warned (France Info) that one should not place too much hope in the Pfizer vaccine because antibodies last only a few months — then disappeared from public communication. ▶ 12:19
    Sources: Pfizer-BioNTech pre-clinical macaque immunogenicity publication
  • Cotton wrote in January 2022 that the methods used in the Pfizer trial cannot guarantee that the results are reliable and faithful to GCP; she presented this to the OPECST (April 2022) and the ANSM (July 2022, behind closed doors). The ANSM told her the primary endpoint was "accepted by every health agency in the world" — leaving, in Cotton's words, three possibilities: mass stupefaction, mass incompetence, or deliberate choice to put a defective product on the market. ▶ 17:12
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022); Cotton OPECST hearing (April 2022); Cotton ANSM hearing (July 2022, closed)
  • Multiple doses were planned from the start: by December 2020 Pfizer was already studying a booster. Antibodies were not measured — Cotton's reading is so they could not be shown to fall. When the public noticed waning at six months, the pre-planned booster was "pulled out of a hat." ▶ 18:22
    Sources: Pfizer booster sub-study (Dec 2020 amendment to C4591001)
  • Serious adverse events are missing from the clinical reports on adults and adolescents — Cotton has spoken to trial-injured participants who suffered severe harm that was never reported. "This is not OK by Good Clinical Practice: in a center, you have someone half-dying and the recruiting doctor doesn't report them." ▶ 21:03
    Sources: Pfizer C4591001 clinical study reports (adult + adolescent)
  • Maxime, age 22, died about 5-6 hours after his first injection while at table with his in-laws. The autopsy claims to find no allergy trace on the injection arm — but in fact examined the other arm, where the adrenaline shot used to try to resuscitate him had been administered. ▶ 22:38
    Sources: Maxime autopsy report (cited in book)
  • "Lucie" was given a vaccine her GP had "kept aside" because the friend-GP couldn't otherwise use the dose within the half-hour — and the GP refused to file a pharmacovigilance report. Cotton: doctors who don't report adverse events are committing a grave breach; pharmacovigilance signals cannot be calculated correctly if reports never reach the system. ▶ 24:00
    Sources: French pharmacovigilance reporting obligations
  • Cotton's prediction: a time will come when it is not anonymous victims dying in obscurity but "daughters of police officers, wives of judges" — then the case dismissals will be revisited. ▶ 27:15

Documents cited

  • Leaked Pfizer-South Africa supply contract (April 2021) — Health Justice Initiative (S. Africa) disclosure
  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 adolescent (12-15) clinical study report (April 2021) — EMA / FDA submissions (court-released)
  • EU Advance Purchase Agreements (Pfizer/BioNTech) — European Ombudsman OI/4/2022/PB
  • FDA Guidance on Development and Licensure of Vaccines to Prevent COVID-19 — FDA CBER, June 2020
  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
  • OPECST hearing of Christine Cotton (April 2022) — Assemblée nationale / Sénat OPECST
YouTube
Christine Cotton : « On a des risques qui sont parfaitement documentés ! » #COVID19
LES INCORRECTIBLES
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-07-16🎙️ Les Incorrectibles (host)📺 LES INCORRECTIBLES⏱ 54 min
“We have risks that are perfectly documented in the laboratories' own files — Pfizer, Moderna, AstraZeneca. A whistleblower is someone who warns of risks. That is exactly what I am doing.”

Key statements

  • Conspiracy Watch describes Cotton's book as anti-vaccination propaganda. Cotton's response: "What interests me is who is paying them?" The site was revealed during a Senate hearing on the Marianne Fund to receive up to 50% public subsidies — so dismissing Cotton's work is publicly subsidized. ▶ 20:08
    Sources: Senate hearing on the Fonds Marianne (2023)
  • After she posted her expertise on LinkedIn to ask peer comment, the account lasted two days. LinkedIn censored the post, she reposted it, they suspended the account. She has since asked to recover it; they refuse. ▶ 22:43
    Sources: Cotton — January 2022 expertise report (LinkedIn post)
  • From January 2021 Cotton saw the problem: no statistically demonstrated efficacy on severe cases, no demonstrated efficacy on adults over 75, only three-month interim analyses — so tolerability could only be claimed over a very short window. ▶ 25:46
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Cotton calls for an audit of every participating trial center: the methodology shows major biases and serious failures that invalidate the conclusions. The audit will determine whether this is deliberate scientific fraud or a chain of malfortunate circumstances tied to the urgency. ▶ 26:15
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • Cotton defines a whistleblower as someone who warns the population of potential risks. The risks she names are documented in the laboratories' own files — Pfizer, Moderna, AstraZeneca — not just mRNA. She has alerted the OPECST and other authorities; in her book she mentions other things she has never made public. ▶ 28:39
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022); OPECST hearing of Christine Cotton (April 2022)
  • After a worrying phone call and the harassment campaign Cotton observed on her LinkedIn profile, she hired a bodyguard ("a guardian angel") for five months. ▶ 30:49
  • 1.2 million adverse-event reports are filed on the EMA database. Doctors under-report — sometimes because they have no time, sometimes because they decide there's no link. "Even if it were only 10 cases, would that be a reason not to take them in charge?" ▶ 34:15
    Sources: EudraVigilance (EMA adverse-event database)
  • Cotton's political supporters at the time: MEP Michèle Rivasi (who co-wrote the book's preface with senator Laurence Muller-Bronn), MEP Virginie Joron, and Nicolas Dupont-Aignan. Cotton: "Today I was with Nicolas Dupont-Aignan… he says the book is very instructive and people should read it." ▶ 39:23
    Sources: Cotton — Tous vaccinés, tous protégés (book preface)
  • On the Raoult / hydroxychloroquine case Cotton declines to take a position because she has not re-run his analyses. But she points out the asymmetry: the ANSM refused Raoult a temporary use authorization (ATU / RTU) — a mechanism created after the Mediator scandal precisely to let an existing approved product be tested in a new indication without a full clinical trial. "Why not raid Pfizer instead?" ▶ 45:37
    Sources: ANSM ATU / RTU regulatory framework; Mediator affair regulatory aftermath
  • Cotton: "As long as we let experts who are not experts come and lecture people whose ankle they don't reach, we get nowhere." She points to Karine Lacombe, who replied to a Cotton tweet asking about a colloquium on vaccine adverse events with "don't come pollute my feed with your fantasies." Cotton: "My fantasies are seeing harassers and the corrupt in the dock." ▶ 51:58

Documents cited

  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • EudraVigilance (EMA) — adverse-event database — adrreports.eu
  • OPECST hearing of Christine Cotton (April 2022) — Assemblée nationale / Sénat OPECST
  • Cotton — Tous vaccinés, tous protégés (Guy Trédaniel, 2023) — book preface by Michèle Rivasi and Laurence Muller-Bronn — Guy Trédaniel
  • ANSM ATU / RTU framework (post-Mediator) — ansm.sante.fr
  • Senate hearing on the Fonds Marianne (2023) — Conspiracy Watch funding disclosure — Sénat — committee record
YouTube
Covid19 - Christine Cotton : "La science ce n'est pas de la politique, c'est de la statistique !"
Sud Radio
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-06-19🎙️ André Bercoff (host)📺 Sud Radio⏱ 31 min
“Science is not politics, not left or right — it is statistics.”

Key statements

  • Developing a drug normally takes 10 to 15 years. Between China sequencing SARS-CoV-2 in March 2020 and the Pfizer vaccine reaching the market, nine months elapsed. Phase 2 began before Phase 1 was complete; Phase 3 began before Phase 2 was complete — unprecedented. ▶ 06:15
    Sources: Pfizer C4591001 Protocol
  • What the 95% efficacy actually covered: only PCR-confirmed mild or moderate COVID cases. The December 2020 report shows no demonstrated efficacy on severe cases and no demonstrated efficacy in the 75+ subgroup. ▶ 10:21
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Despite the report showing no efficacy on severe cases or the 75+, the public discourse was that everyone had to be vaccinated, starting with the elderly. The same flawed three-month interim with half the participants followed for less than two months was reproduced for the 12-15, 5-11 and infant cohorts. ▶ 10:50
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020); Pfizer pediatric trial reports (12-15, 5-11, 6 months-4 years)
  • Pregnant women are always excluded from clinical trials as a protected population. Pfizer's pregnancy-specific trial ended in July 2022 with no released results. Cotton: "We have no clinical trial results for the populations I just listed" — pregnant women, immunocompromised, comorbidities. ▶ 11:47
    Sources: Pfizer pregnancy clinical trial (terminated July 2022, no results released)
  • Science is not politics — it is statistics. Cotton attributes the political polarization around COVID vaccines to harassment networks on social media tied to TV doctors, journalists, and politicians. ▶ 13:47
  • Using the FDA-released trial database and recomputing efficacy on the anti-nucleocapsid serology criterion (which captures actual SARS-CoV-2 infection regardless of symptoms), efficacy is around 55% — not 95%. The result is dependent on the chosen endpoint, and this 55% number was never presented in the clinical reports. ▶ 16:25
    Sources: Pfizer C4591001 trial database (FOIA / court-released)
  • EMA's monovalent Pfizer adverse-event reports stand at 1.2 million, and Cotton estimates a 10× or higher under-reporting factor. The narrative push to declare the vaccine subject "old news" is a way of trying to escape responsibility. ▶ 19:21
    Sources: EudraVigilance (EMA adverse-event database)
  • Cotton's January 2022 expertise calls for a temporary suspension and an audit of how the trial was actually conducted on the ground. The more the FOIA'd databases come out, the more discrepancies appear. ▶ 21:06
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • States signed procurement contracts that exonerate the labs from liability. If trials are not reliable, the contracts should be revisited and the labs forced to pay — there is no reason for taxpayers to fund adverse-event compensation on the basis of trials that are inadmissible. ▶ 21:50
    Sources: EU Advance Purchase Agreements (Pfizer/BioNTech)
  • Two days after Cotton posted her report on LinkedIn, her profile was visited by the WHO, US State Department, Apple, the French Interior Ministry, the Ministry of the Armed Forces, the Gendarmerie Nationale — "not the people you debate with." ▶ 29:20
    Sources: Cotton — January 2022 expertise report (LinkedIn post)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer pediatric trial reports (12-15, 5-11, 6 months-4 years) — FDA / EMA submissions
  • Pfizer pregnancy clinical trial (terminated July 2022, no results released) — ClinicalTrials.gov record (NCT04754594)
  • Pfizer C4591001 trial database (court-released) — Court orders following FOIA / PHMPT litigation
  • EudraVigilance (EMA) — adverse-event database — adrreports.eu
  • EU Advance Purchase Agreements (Pfizer/BioNTech) — European Ombudsman OI/4/2022/PB
  • HAS (Haute Autorité de Santé) — 2 February 2021 opinion on AstraZeneca AZD1222 — has-sante.fr
  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
YouTube
« J'ai découvert la face cachée de l'industrie pharmaceutique » – Christine Cotton
Epoch Times France
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-07-05🎙️ Epoch Times France (interviewer)📺 Epoch Times France⏱ 48 min
“There was no statistical proof of any effect on severe forms — for the simple reason that there weren't enough severe cases in the trial to demonstrate a difference between placebo and vaccine.”

Key statements

  • A major statistical bias in the Pfizer trial: not every participant is systematically given a PCR test, so you do not know who actually had COVID. The trial was designed in a way that produces this bias — a methodological choice that is itself a GCP deviation. ▶ 07:36
    Sources: Pfizer C4591001 Protocol
  • Pfizer's primary immunogenicity marker — neutralizing antibodies — was measured only two months after dose 2. A vaccine is meant to raise antibodies; in a global emergency one would expect more measurement, not less. Antibodies were not measured again until six months after dose 2 — the window where decay would have shown up was deliberately not sampled. ▶ 09:54
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
  • We have known since December 2020 that Pfizer was planning to study a booster — a third dose in case of waning immunity. ▶ 11:50
    Sources: Pfizer booster sub-study (Dec 2020 amendment to C4591001)
  • Using the FDA-released SAS data tables and recomputing efficacy on the anti-nucleocapsid serology endpoint — which actually identifies who was infected during the trial regardless of symptoms — Cotton obtains roughly 55% efficacy, not 95%. The under-tested vaccine group dropped the count of registered cases; this 55% figure was never reported by Pfizer. ▶ 13:53
    Sources: Pfizer C4591001 trial database (FOIA / court-released SAS tables)
  • On severe cases the December 2020 result is statistically meaningless: 1 severe case in the vaccine arm vs. 3 in the placebo arm, on ~18,000 people per arm — about 4 severe cases on ~36,000 participants. "It was impossible to demonstrate any efficacy of the vaccine on severe cases. It's statistical — it's black or white." ▶ 15:56
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Brooke Jackson, ex-regional director at Ventavia Research Group, blew the whistle on GCP violations on three sites that enrolled about 1,000 participants in the Pfizer Phase 2-3. If the trial was run that way at those sites, there is no reason to think it was better elsewhere. ▶ 17:49
    Sources: Brooke Jackson — BMJ whistleblower report (Thacker, 2 November 2021)
  • The Augusto Roux case in Buenos Aires (Argentina) — a lawyer who nearly died during the Pfizer trial, suffered myocarditis/pericarditis, and whose data were transformed so the event does not appear in the results. The Argentina site was a single military hospital that recruited 5,700 participants — a major fraction of the trial. "This is obviously a center to audit urgently." The agencies did nothing. ▶ 18:40
    Sources: Augusto Roux medical file; Pfizer C4591001 clinical study report (adult)
  • Maddie de Garay — adolescent participant in Pfizer's 12-15 trial — suffered a serious adverse event that was not reported as-such in the clinical study report or the database. Cotton: "Tolerability false. That's starting to add up." ▶ 20:18
    Sources: Maddie de Garay testimony to Sen. Ron Johnson; Pfizer C4591001 adolescent (12-15) clinical study report
  • Commercial Pfizer vials don't contain the same ingredients as the trial vials: Pfizer modified its manufacturing process, reducing the proportion of integral mRNA. The ANSM (French agency) claims it performs quality controls but no inspection reports have ever been published. ▶ 20:59
    Sources: Pfizer C4591001 Protocol (Process 2 amendment); ANSM quality control records (not public)
  • Claims that the vaccine reduces transmission do not come from clinical trials but from observational real-world studies, which the HAS itself ranks as the lowest level of scientific evidence for drugs. Cotton has personally never conducted such an analysis in 23 years; she ran ~1,000 projects and only three were observational, all prospective. ▶ 22:14
    Sources: HAS — Niveaux de preuve scientifique (drug evaluation grid)
  • Since 1995 Pfizer has been implicated in around forty cases for scientific fraud, wild clinical trials, corruption of decision-makers, and dissemination of false information — paying roughly $6.5 billion in penalties. Cotton: not isolated cases, but corporate culture. ▶ 23:54
    Sources: Pfizer settlement and litigation history (1995-2023)
  • From October 2020 there exists a publicly available FDA YouTube presentation listing the adverse events to actively monitor for COVID vaccines — and the list matches what was later observed: myocarditis, pericarditis, blood-clotting problems, thromboses, neurological problems. The harms were anticipated. ▶ 31:32
    Sources: FDA VRBPAC meeting (22 Oct 2020) — adverse events of special interest slide deck
  • Risk Management Plans drafted by the labs at authorization and updated as risks emerge formally list the populations on which there are no data: pregnant or lactating women, immunocompromised patients, patients with comorbidities — together with unknowns about duration of protection and absence of interaction studies with other vaccines. ▶ 35:00
    Sources: Comirnaty Risk Management Plan (EMA, Dec 2020 + updates)
  • Despite EMA, WHO and ANSM recommending vaccination for pregnant women, scientific publications subsequently showed that the spike protein circulates into the fetus. Cotton's position is not "don't get vaccinated" but "give people complete information so they can decide." ▶ 36:55
    Sources: Peer-reviewed publications on placental transfer of spike protein
  • Cotton's January 2022 expertise figures in the French criminal complaint for poisoning filed against X. It is currently dismissed and under appeal. Her position: if trials are unreliable, the procurement contracts exonerating the labs from adverse-event liability should be revisited — and the labs made to pay. ▶ 45:37
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022); French criminal complaint for poisoning (plainte contre X)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 trial database — SAS tables (court-released) — Court orders following FOIA / PHMPT litigation
  • Brooke Jackson — BMJ whistleblower report (Thacker, 2 November 2021) — BMJ 2021;375:n2635
  • Augusto Roux medical file — Personal records, cited in Argentine court filings
  • Maddie de Garay testimony to Sen. Ron Johnson — Sen. Ron Johnson press conference, recordings publicly available
  • FDA VRBPAC meeting (22 October 2020) — adverse-event monitoring slides — FDA / CDC public materials, available on the FDA YouTube channel
  • Comirnaty Risk Management Plan (December 2020 + updates) — EMA EPAR archive
  • HAS — Niveaux de preuve scientifique grid — has-sante.fr
  • Pfizer settlement and litigation history (1995-2023) — US DOJ press releases, SEC filings
  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
  • French criminal complaint for poisoning (plainte contre X, including Cotton expertise) — Paris criminal court filings
YouTube
Pfizer : scandaleuses révélations sur l'essai clinique
Décoder l'éco
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-06-15🎙️ Décoder l'éco (host) with co-guest Pierre (OpenVAET, anonymous data analyst)📺 Décoder l'éco — YouTube channel⏱ 59 min
“The quasi-totality of people who received a Pfizer vaccine got a product that was not the one of the trial. Of the 40,000 in the study, you found only 250 who received the same one.”

Key statements

  • Cotton, biostatistician for 23 years and former CEO of a CRO repeatedly audited against GCP, wrote her January 2022 expertise of the Pfizer C4591001 trial as a critique against Good Clinical Practice standards. ▶ 02:01
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022); ICH-GCP guidelines
  • The first Pfizer C4591001 report — the one announcing 95% efficacy — dates from December 2020 and is the foundation document Cotton dissects. ▶ 03:55
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • PCR-positive participants in Argentina (Buenos Aires military hospital, ~5,700 subjects) had their samples shipped to Pearl River, a Pfizer-controlled lab in the United States — only the central test was authoritative, even when it conflicted with a positive local test. ▶ 08:05
    Sources: Pfizer C4591001 Protocol
  • The trial's stated objective was to prevent symptomatic COVID — never to prevent transmission. The final efficacy analysis was triggered when 164 cases (vaccine + placebo) had accumulated. ▶ 12:19
    Sources: Pfizer C4591001 Protocol
  • Pregnant or breastfeeding women, immunocompromised patients, and patients with comorbidities or autoimmune disease were excluded or so under-represented that no subgroup analysis exists for them. Co-administration with other vaccines was not studied; transmission was not studied; asymptomatic cases were not studied. ▶ 13:15
    Sources: Pfizer C4591001 Protocol; Comirnaty Risk Management Plan (Dec 2020, EMA)
  • The FDA, in October 2020, allowed labs to submit results based on three months of follow-up maximum (with half of participants followed less than two months), whereas previous vaccine guidance required six months to a year. ▶ 14:36
    Sources: FDA October 2020 vaccine guidance amendment
  • Symptomatic-PCR-confirmed endpoint is biased: participants self-report symptoms, vaccine-group antipyretic use is ~3.5× higher than placebo, and antipyretics suppress fever — a COVID symptom. No symptoms, no test, no COVID — to the vaccine's benefit. ▶ 15:04
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020) — antipyretic use tables
  • Preclinical monkey data and Phase 1 already showed a decline of neutralizing antibodies starting at two months. Pfizer deliberately did not measure antibody titres at three months post-dose-2 — the timepoint when the drop would have been visible. ▶ 19:02
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule); Pfizer preclinical macaque study
  • Pfizer vaccinated the placebo group shortly after the first interim analysis, destroying the long-term control comparison. Cotton notes this is only ethically justified for cancer trials where the active product is clearly superior — not for a vaccine. ▶ 20:05
    Sources: Pfizer C4591001 Protocol (amendment unblinding/crossover)
  • Pierre (OpenVAET) summarizes the database-level red flags: the trial was not truly blinded; vaccine-group subjects were less likely to be tested when symptomatic; 301 subjects disappeared from the database (with Argentina as the major outlier); reports to regulators disagree with the database; and the marketed product is not the one tested ("bait and switch"). ▶ 26:26
    Sources: Pfizer C4591001 court-released database (PHMPT / FOIA)
  • Of ~44,000 trial participants, only about 250 received the Process-2 manufactured product that was later distributed to the public. The quasi-totality of vaccinated people thus received a product never validated at trial scale. ▶ 27:28
    Sources: Pfizer C4591001 Protocol (Process 2 amendment); Pfizer C4591001 trial database (court-released)
  • Russian hackers leaked Pfizer–EMA correspondence in which the EMA itself flagged a mRNA-integrity problem: intact-mRNA levels differed between trial-product and marketed product. MEP Michèle Rivasi has publicly highlighted this point. ▶ 28:15
    Sources: EMA-Pfizer leaked correspondence (Dec 2020, hacked)
  • Augusto Roux (Argentine lawyer, Pfizer adult trial, dose 2 on 9 Sept 2020) fainted and was hospitalized with pericarditis. BioNTech intervened to reclassify the pericarditis as suspected COVID. The Argentine site director Fernando Polack — principal investigator and signatory of the 95% efficacy paper — sought to have him classified as mentally ill. ▶ 38:53
    Sources: Augusto Roux medical file; Polack et al. NEJM 2020 (C4591001 publication)
  • Of the 301 missing subjects in the database, 111 (36.9%) were in Argentina alone — yet only 6 documented duplicates exist trial-wide. Subject deletions are normally documented via a specific form; the volume here is unexplained. ▶ 42:25
    Sources: Pfizer C4591001 court-released database (PHMPT / FOIA); ICON Firecrest data-management platform documentation
  • Cotton and OpenVAET wrote to FDA's Peter Marks (Director of CBER) about the database anomalies. They received an acknowledgement from a deputy but no substantive response — "about two and a half months ago, and we're still waiting." ▶ 43:09
    Sources: Correspondence with FDA / CBER (Peter Marks)
  • The 250 subjects who received Process 2 (from 19 October 2020 onward) had an adverse-event reporting rate 2.7× higher than subjects who received the higher-purity (Process 1) product — and Process 1 itself was "already not great." ▶ 47:35
    Sources: Pfizer C4591001 court-released database (PHMPT / FOIA)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 court-released trial database (XPT / SAS files) — PHMPT / FOIA disclosures (phmpt.org)
  • EMA-Pfizer leaked correspondence (Dec 2020, hacked) — Russian-hacker disclosure; coverage in BMJ and elsewhere
  • Polack et al. NEJM 2020 — C4591001 efficacy publication — New England Journal of Medicine
  • Correspondence with FDA / CBER (Peter Marks) — Cotton / OpenVAET personal correspondence
  • Brook Jackson — Ventavia whistleblower BMJ report (Thacker, 2021) — BMJ 2021;375:n2635
  • ICON Firecrest data-management platform documentation — ICON plc — clinical-systems product page
YouTube
Christine Cotton - Biostatisticienne - Lanceuse d'alerte
Elo Veut Savoir
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-05-30🎙️ Élo Veut Savoir (Quebec-based independent host)📺 Élo Veut Savoir — YouTube channel⏱ 51 min
“Why didn't they measure antibodies at three months post-dose 2? So they wouldn't have to show the drop. They already knew from December 2020 — the HAS opinion notes Pfizer was already studying a booster.”

Key statements

  • Trial-participant adverse events are missing or not reported: Maddie de Garay (US, Pfizer 12-15 trial, 35 serious events) and Augusto Roux (Argentina, Pfizer adult trial, nearly died) called Cotton directly; neither appears properly in the trial database. ▶ 07:24
    Sources: Augusto Roux medical file; Maddie de Garay testimony to Sen. Ron Johnson
  • Cotton's January 2022 expertise frames the Pfizer trial against ICH Good Clinical Practice — if data are not valid, results are not valid; if the primary endpoint is wrongly chosen, the demonstrated efficacy is false. Transmission was not studied, asymptomatic cases were not studied, and there was no demonstrated effect on severe cases. ▶ 09:29
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022); ICH-GCP guidelines
  • Pfizer also collected anti-nucleocapsid serology — the marker that catches anyone who actually had COVID during the trial — but never published the analysis. Computed on the court-released database, Cotton finds about 55% efficacy on this marker, versus the published 95% on PCR-confirmed symptomatic cases. ▶ 12:46
    Sources: Pfizer C4591001 court-released trial database (PHMPT / FOIA)
  • France's HAS (Haute Autorité de Santé) noted, in writing, in December 2020 that Pfizer was already studying a booster — proving they knew protection would not last when the original two-dose regimen was sold to the public. ▶ 17:45
    Sources: HAS opinion on Comirnaty (December 2020)
  • Cotton's VAERS analysis (more than 400,000 lines) found over 60% of vaccine-associated deaths occurred within 21 days of injection. Reading the individual death reports, she encountered grandparents found dead the next morning and young people dying at their desks during math class. ▶ 22:24
    Sources: VAERS public dataset (US adverse-event reports)
  • The EU Risk Management Plan formally records, since December 2020, that pregnant women are not included in the trial and that autoimmune-disease patients have not been tested. Pregnant women were then classified as a high-risk population and prioritized for vaccination. ▶ 23:21
    Sources: Comirnaty Risk Management Plan (December 2020, EMA)
  • An FDA presentation in October 2020 listed expected adverse events including neurological and blood disorders — but did not anticipate menstrual disturbances, which today account for a substantial share of the EU adverse-event database. ▶ 31:09
    Sources: FDA VRBPAC meeting (Oct 2020) — adverse-events-to-monitor slides
  • Of 77 trial pregnancies, Cotton finds more miscarriages in the placebo arm than in the vaccine arm — which she reads as evidence that the trial data are unreliable, given the known under-reporting of serious events such as the Augusto Roux and Maddie de Garay cases. ▶ 34:35
    Sources: Pfizer C4591001 court-released trial database (PHMPT / FOIA)
  • In France, a criminal complaint for poisoning has been filed. Cotton helped re-read the complaint and drafted the sections covering her expertise report — arguing that if the registration trial is fraudulent, manufacturers, not the state, should bear the cost of adverse-event compensation. ▶ 39:51
    Sources: French criminal complaint for poisoning (2022); Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • After Cotton posted her January 2022 expertise on LinkedIn, the post was visited within two days — before LinkedIn closed her account — by 133 lawyers, plus visitors from Apple, the US State Department, the WHO, and others. ▶ 40:50
    Sources: Cotton — January 2022 expertise report (LinkedIn post, screenshots)

Documents cited

  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 court-released trial database (XPT / SAS) — PHMPT / FOIA disclosures (phmpt.org)
  • Comirnaty Risk Management Plan (December 2020, EMA) — EMA EPAR archive
  • VAERS public dataset (US adverse-event reports) — openvaers.com / CDC WONDER
  • HAS opinion on Comirnaty (December 2020) — has-sante.fr archive
  • FDA VRBPAC meeting (October 2020) — adverse-events-to-monitor slides — FDA / CDC public materials
  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
  • Maddie de Garay testimony (Sen. Ron Johnson press conference) — Sen. Ron Johnson public events
  • Augusto Roux medical file (Argentine trial participant) — Personal records, cited in legal filings
YouTube
REVAV AG Intervention de Christine Cotton Biostatisticienne octobre 2022
Guillaume Ageorges
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-10-31🎙️ Guillaume Ageorges (host, REVAV AG general assembly)📺 Guillaume Ageorges — YouTube channel (REVAV AG)⏱ 29 min
“The biggest cover-up of the COVID clinical trials is this: they did not measure antibodies at three months because they knew they would drop. They knew from the start — and the HAS opinion shows Pfizer was already studying a booster in December 2020.”

Key statements

  • A 22 October 2020 FDA presentation lists possible adverse-event outcomes to monitor: Guillain-Barré, encephalomyelitis, transverse myelitis, convulsions, narcolepsy, anaphylaxis, myocarditis, autoimmune disease, death, pregnancy complications, thrombocytopenia, thromboembolism, and pediatric multisystem inflammatory syndrome (PIMS). The slide subsequently disappeared from regulatory meetings. ▶ 03:42
    Sources: FDA VRBPAC meeting (22 October 2020) — adverse events of special interest slides
  • Pfizer's preclinical macaque data show neutralizing antibodies rising at 21-28 days, peaking, and dropping by day 56 — a curve visible in the FDA briefing dossier before the first authorization. Anti-N antibodies were not available so neutralizing antibodies were chosen as the immunity marker. ▶ 05:16
    Sources: Pfizer preclinical macaque study; FDA VRBPAC briefing dossier (Dec 2020)
  • In November 2020, former French health minister Philippe Douste-Blazy said publicly: "It's nice, vaccines, but let's not get carried away — protection only lasts about two months." He subsequently disappeared from media circulation. ▶ 07:01
    Sources: Douste-Blazy public interview (Nov 2020)
  • Computed against anti-nucleocapsid seroconversion — the marker that catches anyone who actually caught COVID during the trial — efficacy is about 55-56%, not 95%. ▶ 10:03
    Sources: Pfizer C4591001 court-released trial database (PHMPT / FOIA)
  • The C4591001 protocol's visit schedule has a gaping hole: between day 56 and 6 months, no antibody titre is taken. A 3-month measurement would have shown the drop — and is the single most important omission of the Pfizer trial and of every COVID vaccine trial. ▶ 13:48
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
  • Pfizer did not measure antibodies at three months because they already knew the drop would force regulators either to refuse authorization or to announce up front that boosters would be needed — invalidating the "two doses and back to normal life" narrative. ▶ 14:39
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule); HAS opinion on Comirnaty (December 2020)
  • The November 2020 Risk Management Plan lists the same gaps as the September 2022 update — pregnant or breastfeeding women, immunocompromised patients, autoimmune disease, no co-administration interaction study. Anaphylaxis was the only item removed ("known now"); everything else remained an unknown. ▶ 19:52
    Sources: Comirnaty Risk Management Plan (Nov 2020, EMA); Comirnaty Risk Management Plan (Sept 2022, EMA)
  • Direct evidence of GCP fraud comes from Brook Jackson (Ventavia, US), Augusto Roux (Argentina — multiple serious events not in the clinical report), and Maddie de Garay (US adolescent trial). Tolerance evaluation in the Pfizer trial is therefore false at face value. ▶ 22:47
    Sources: Brook Jackson — Ventavia whistleblower BMJ report (Thacker, 2021); Augusto Roux medical file; Maddie de Garay testimony to Sen. Ron Johnson
  • Per a paper by the head of French CRPV (Joëlle Micallef), only 1-10% of adverse events are reported. France's ANSM database holds about 182,000 Pfizer-vaccine cases, of which 25% are serious — extrapolated to true incidence, the figures are an order of magnitude larger. ▶ 25:21
    Sources: ANSM pharmacovigilance reports; Micallef et al. — paper on adverse-event under-reporting
  • France's regional pharmacovigilance centres (CRPV) appear to systematically push back imputability — demanding extra exams and dragging out cases — rather than declaring a vaccine link. Cotton works closely with REACT C19 patients (small-fiber neuropathy, tinnitus, neurological symptoms) who are largely abandoned by the medical system. ▶ 28:14
    Sources: ANSM pharmacovigilance reports; REACT C19 patient association — testimonies

Documents cited

  • FDA VRBPAC meeting (22 October 2020) — adverse events of special interest slides — FDA YouTube channel / VRBPAC public materials
  • Pfizer preclinical macaque study (incl. neutralizing antibody curves) — FDA briefing document, Dec 2020 VRBPAC
  • Pfizer C4591001 Protocol (immunogenicity schedule) — NEJM supplementary materials
  • Pfizer C4591001 court-released trial database — PHMPT / FOIA disclosures (phmpt.org)
  • Comirnaty Risk Management Plan (Nov 2020 & Sept 2022, EMA) — EMA EPAR archive
  • HAS opinion on Comirnaty (December 2020) — has-sante.fr archive
  • Brook Jackson — Ventavia whistleblower BMJ report — BMJ 2021;375:n2635 (Thacker)
  • ANSM pharmacovigilance reports — ansm.sante.fr
  • Micallef et al. — paper on adverse-event under-reporting (1-10% reported) — French pharmacovigilance literature
YouTube
[DEBRIEF] La biostatisticienne Christine Cotton sur l'efficacité du vaccin anti-COVID Pfizer
Michèle Rivasi
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-05-02🎙️ Michèle Rivasi (MEP, Europe Écologie Les Verts) — post-OPECST debrief📺 Michèle Rivasi — YouTube channel⏱ 49 min
“On the basis of the December 2020 evidence, no authorization should have been granted for these products — three months' follow-up is insufficient, efficacy is biased, and the benefit-risk ratio is, plainly, false.”

Key statements

  • Cotton was heard in camera by the OPECST (French Parliamentary Office for Scientific and Technological Assessment) following a 33,000-signature petition on COVID-vaccine adverse events. The hearing brought together deputies and senators across the political spectrum. ▶ 03:07
    Sources: OPECST hearing transcript (in camera, 2022); French Senate petition on COVID-vaccine adverse events (2022)
  • The 95% headline corresponds to only 0.84% absolute reduction in symptomatic-PCR-confirmed COVID. Recasting the same data as an absolute-risk difference makes the result look very different. ▶ 09:24
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Vaccine-group participants used antipyretics more often than placebo; participants self-reported symptoms; PCR testing was triggered only by symptom reporting. No symptoms → no test → no COVID counted as a success for the vaccine. ▶ 10:33
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020) — antipyretic use tables
  • Neutralizing antibody titres were already declining two months after dose 2 by December 2020 — visible in both the preclinical macaque data and the human Phase 1-2. Pfizer chose to take no further measurement, so the December 2020 dossier did not show the decline. ▶ 13:05
    Sources: Pfizer preclinical macaque study; Pfizer C4591001 Protocol (immunogenicity schedule)
  • France's HAS, in December 2020, noted that Pfizer was already studying a booster. The progression from 2 → 3 → 4 doses, with the US now discussing a fifth, was therefore pre-known, not discovered later. ▶ 14:28
    Sources: HAS opinion on Comirnaty (December 2020)
  • Maddie de Garay (Pfizer 12-15 trial, Cincinnati site) suffered vomiting, nausea, memory loss; is wheelchair-bound and fed by gastric tube. None of this appears in the clinical report. Cotton learned of the case through Sen. Ron Johnson's victim-testimony hearings. ▶ 17:48
    Sources: Maddie de Garay testimony to Sen. Ron Johnson; Pfizer C4591001 (12-15 yrs) clinical study report
  • Across the adult, adolescent, and 5-11 reports, there is no statistically significant effect on severe cases — there were too few severe cases in the trial to demonstrate one. The official narrative that the vaccine "prevents severe disease" is therefore not supported by the registration trials. ▶ 18:06
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020); Pfizer pediatric trial reports (12-15 yrs, 5-11 yrs)
  • Pregnant women, immunocompromised patients, patients with comorbidities (diabetes, COPD), and those over 75 with sufficient power were not studied in the trial — yet were the first vaccinated. Co-administration with the flu vaccine was authorized despite no interaction study. ▶ 21:59
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020); Comirnaty Risk Management Plan (Dec 2020, EMA)
  • The December 2020 OPECST report itself records that on the first day of UK vaccination, severe allergic reactions occurred, and that people carrying an adrenaline pen should not be vaccinated. That warning was disregarded by French policy. ▶ 28:26
    Sources: OPECST report (December 2020) on COVID-19 vaccination
  • At 6-month follow-up the trial shows 15 deaths in the vaccine arm and 14 in placebo, with 2 COVID deaths in placebo and 1 in vaccine — no statistically meaningful effect on COVID mortality, and no effect on total mortality. ▶ 35:02
    Sources: Pfizer C4591001 6-month follow-up clinical study report
  • If this trial is accepted, it is the end of 30-40 years of reliable clinical research. McKinsey, in a self-congratulatory article, says the next target is 100-day vaccines — Cotton notes that 325-day vaccines already produced this much harm. ▶ 39:44
    Sources: McKinsey article on accelerated vaccine development (2022); ICH-GCP guidelines

Documents cited

  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 6-month follow-up clinical study report — FDA briefing documents
  • Pfizer pediatric trial reports (12-15 yrs, 5-11 yrs) — FDA / EMA submission archives
  • Comirnaty Risk Management Plan (December 2020, EMA) — EMA EPAR archive
  • HAS opinion on Comirnaty (December 2020) — has-sante.fr archive
  • OPECST report on COVID-19 vaccination (December 2020) — Assemblée nationale / Sénat archive
  • Maddie de Garay testimony to Sen. Ron Johnson — Sen. Ron Johnson public events
  • ANSM pharmacovigilance reports — ansm.sante.fr
  • McKinsey article on accelerated vaccine development (2022) — McKinsey.com — health-industry briefing
YouTube
Christine Cotton révèle le scandale des vaccins anticovid !
Nicolas Dupont-Aignan
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-06-14🎙️ Nicolas Dupont-Aignan (politician, founder of Debout la France)📺 Nicolas Dupont-Aignan — YouTube channel⏱ 9 min
“Marketing authorizations were issued from three-month clinical trials instead of two years. Pregnant women, the immunocompromised, and the over-75s were not included. Yet they were vaccinated.”

Key statements

  • Her expertise of the Pfizer C4591001 trial demonstrates serious deficiencies and methodological biases that invalidate the results. She calls publicly for an audit of every participating trial center. ▶ 00:52
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • Marketing authorizations were issued on the basis of three-month trials rather than the planned two years. ▶ 01:36
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • Pregnant women, immunocompromised patients, and adults over 75 were not included in the registration trial — yet were subsequently vaccinated. ▶ 01:44
    Sources: Pfizer C4591001 Protocol
  • Transmission was not tested in the trial — a fact Pfizer subsequently acknowledged before the European Parliament (Janine Small testimony). ▶ 01:56
    Sources: European Parliament COVI committee hearing (10 Oct 2022) — Janine Small testimony
  • The December 2020 interim report shows no statistically demonstrated effect on severe cases and no demonstrated effect in the 75+ subgroup. ▶ 02:10
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Serious adverse events suffered by trial participants are missing from the database: Augusto Roux (Argentina, Pfizer adult trial, nearly died — full medical record exists) and Maddie de Garay (US, Pfizer adolescent trial, 35 serious events, wheelchair-bound with a gastric tube — testified to Senator Ron Johnson). ▶ 04:43
    Sources: Augusto Roux medical file; Maddie de Garay testimony to Sen. Ron Johnson
  • EU member states absorbed liability for Pfizer in the (hidden) procurement contracts. If clinical trials are shown to be fraudulent, states can in principle turn against the laboratories — and taxpayers stop subsidizing harm compensation. ▶ 05:37
    Sources: EU Commission / Pfizer vaccine procurement contracts (Advance Purchase Agreements, redacted)

Documents cited

  • Christine Cotton — Expertise report (January 2022) — christinecotton.com
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • European Parliament COVI committee — Janine Small testimony (10 Oct 2022) — European Parliament hearing archive
  • EU Advance Purchase Agreements (Pfizer/BioNTech) — European Ombudsman case OI/4/2022/PB
  • Augusto Roux medical file (Pfizer adult-trial participant, Argentina) — Personal records, cited in court filings
  • Maddie de Garay testimony to Sen. Ron Johnson (US Senate event) — Sen. Ron Johnson press conference, recordings publicly available
YouTube
COVID : les vérités cachées de la politique vaccinale - Christine Cotton
Ligne Droite • La matinale de Radio Courtoisie
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-06-08🎙️ Valentin Tomas (host) with Didier Maïsto (Thursday co-host)📺 Radio Courtoisie — Ligne droite, la matinale⏱ 42 min
“I have been making this claim for a year and a half. I have had no lawsuit, and not a single person in the world has managed to produce the slightest argument that my analysis is wrong.”

Key statements

  • Pfizer CEO Albert Bourla himself has acknowledged the mRNA technology had never previously been used in a marketed vaccine or medicine. Authorizing it in 9 months for a new disease drove much of the public's vaccine hesitancy. ▶ 04:50
    Sources: Albert Bourla — public statements / Pfizer interviews
  • Didier Maïsto enumerates the registration gaps from Cotton's report: severe adverse events not studied; follow-up too short; high-risk populations not studied; transmission, asymptomatic infection, mortality, co-infections, virus evolution, duration of protection, antibody waning — all left unstudied. ▶ 07:03
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • Cotton uses the phrase "experts without expertise" for the medical figures on TV during the crisis: most never wrote a protocol or actively contributed to a clinical trial — and none of them is a biostatistician. ▶ 08:04
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • The 95% figure is a ratio computed on 8 vs 162 PCR-confirmed symptomatic cases. As an absolute-risk difference, the same numbers yield 0.84% — and the underlying endpoint counts only mild or moderate PCR-confirmed COVID seven days after dose 2. ▶ 11:52
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Every COVID-vaccine authorization relied on an interim analysis: a study designed to last two years was decided on three months of follow-up, with half of participants followed less than two months. ▶ 12:53
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • Because of the methodological flaws, the benefit-risk ratio announced by Pfizer and accepted by regulators is false, full stop. Despite 18 months making this claim publicly, Cotton has faced no lawsuit and no one in the world has rebutted her analysis. ▶ 15:03
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • After Cotton posted her January 2022 expertise on LinkedIn, 133 lawyers visited her profile within two days — before LinkedIn closed her account on the pretext that she was sharing false information. ▶ 15:12
    Sources: Cotton — January 2022 expertise report (LinkedIn post, screenshots)
  • Maddie de Garay enrolled with her two siblings in the 12-15 trial; she suffered more than 30 serious adverse events with permanent disability and is now in a wheelchair with a gastric tube. Two effects vaguely appear in the clinical report; nothing reflects the gravity of her case. ▶ 18:21
    Sources: Maddie de Garay testimony to Sen. Ron Johnson; Pfizer C4591001 (12-15 yrs) clinical study report
  • Brianne Dressen (AstraZeneca trial, US) alerted for months about severe neurological effects she suffered during the trial. Health authorities worldwide systematically refused to listen to trial-arm participants reporting that they were nearly killed by the vaccine. ▶ 19:49
    Sources: Brianne Dressen — public testimony (REACT19, US Senate)
  • Europe's EMA database holds about 1.2 million adverse-event reports for COVID vaccines. With reporting estimated between 1% and 10%, the underlying incidence is somewhere between 12 million and 120 million cases — myocarditis and pericarditis are among the few signals officially recognized. ▶ 27:09
    Sources: EudraVigilance / EMA adverse-event database
  • In December 2020 there was no statistically demonstrated efficacy in the over-75 subgroup and no demonstrated effect on severe cases. Vaccinating the over-75s — those most affected by COVID mortality — was therefore done in the absence of trial-based evidence. ▶ 30:49
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Cotton describes her in-camera testimony to OPECST and the June 2022 written report that followed: the parliamentary office wrote that victims should be recognized and supported. A final version was promised for autumn 2022 — and is still pending at the time of recording. ▶ 39:49
    Sources: OPECST report on COVID-19 vaccine adverse events (June 2022 draft)

Documents cited

  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
  • Cotton — book Tous vaccinés, tous protégés ? (Guy Trédaniel, 2023) — Guy Trédaniel éditeur
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 (12-15 yrs) clinical study report — FDA / EMA submission archives
  • Comirnaty Risk Management Plan (December 2020, EMA) — EMA EPAR archive
  • EudraVigilance / EMA adverse-event database — adrreports.eu
  • ANSM pharmacovigilance reports — ansm.sante.fr
  • OPECST report on COVID-19 vaccine adverse events (June 2022 draft) — Assemblée nationale / Sénat archive
  • Maddie de Garay testimony to Sen. Ron Johnson — Sen. Ron Johnson public events
  • Brianne Dressen — public testimony — REACT19, US Senate hearings
  • Albert Bourla — public statements / Pfizer interviews — Pfizer press materials
YouTube
Actualité de la semaine et invitée exceptionnelle, la biostatisticienne Christine COTTON
Ensemble Pour Les Libertés
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-02-11🎙️ Martine Wonner (MP, physician) and Steve Ohana (host)📺 Ensemble Pour Les Libertés⏱ 68 min
“No symptoms, no test, no Covid. In the vaccine group, 3 to 4 times more people took antipyretics. So I suppress symptoms — no test, no Covid. My 95% is wrong.”

Key statements

  • The biostatistician is the guarantor of an essai's methodology — calculating the sample size, writing the protocol, running the analyses. Doctors are not equipped to read the resulting tables; they typically call statisticians for help. ▶ 40:07
    Sources: ICH-GCP guidelines
  • The 95% efficacy headline comes from a primary endpoint defined as a first occurrence of PCR-confirmed symptomatic COVID counted seven days after dose 2 — a participant-driven case definition. ▶ 44:21
    Sources: Pfizer C4591001 Protocol
  • Symptoms triggered by the vaccine itself (chills, fever, diarrhea, vomiting) overlap with COVID symptoms. Doctors couldn't tell them apart, so testing was often skipped — "no test, no Covid." ▶ 46:47
    Sources: Pfizer C4591001 Protocol
  • Vaccine-arm participants took antipyretics roughly 3 to 4 times more often than placebo. Suppressed symptoms meant no testing — and the headline 95% efficacy figure is therefore wrong. ▶ 47:29
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020) — antipyretic use tables
  • The second major problem: no antibody titre measurement at three months post-dose 2. Had Pfizer measured at that timepoint, the waning of protection would have been visible before September 2021's booster announcement. ▶ 48:50
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
  • Participants were supposed to be followed 24 months. Interim analyses leading to marketing authorization for an accelerated-development product after only three months of follow-up is, in Cotton's words, unprecedented. ▶ 49:24
    Sources: Pfizer C4591001 Protocol
  • An October 2021 report on the 5-11 trial explicitly states the sample size is too small to detect myocarditis. Small samples can't surface rare serious harms — which makes post-authorization follow-up all the more crucial. ▶ 51:50
    Sources: Pfizer C4591001 pediatric (5-11 yrs) clinical study report (October 2021)
  • Maddie de Garay, a 12-15 trial participant, suffered 35 adverse events and is now wheelchair-bound with a gastric feeding tube. Her serious adverse event is not in the clinical report. ▶ 52:37
    Sources: Pfizer C4591001 pediatric (12-15 yrs) clinical study report
  • Senator Ron Johnson is collecting adverse-event testimony from trial victims who otherwise have no recourse, and Cotton notes there is pressure to silence such victims. ▶ 53:13
    Sources: Sen. Ron Johnson testimony series (US Senate)
  • Real-world protection lasts about four months — meaning a booster every four months. The HAS December 2020 advisory already noted Pfizer was studying boosters at that time. ▶ 54:01
    Sources: HAS opinion (December 2020) on Comirnaty
  • These vaccines were not designed to block transmission. HAS and ANSM both confirm transmission was not studied in the trial — anyone claiming otherwise is engaged in disinformation. ▶ 55:19
    Sources: Pfizer C4591001 Protocol; HAS opinion on Comirnaty
  • A Santé publique France preprint shared on her Twitter shows the booster has no significant effect under age 80 — undercutting the pass vaccinal's stated public-health rationale. ▶ 59:50
    Sources: Santé publique France preprint (booster effectiveness)
  • The Comirnaty package leaflet states pregnant women should be vaccinated only if benefits outweigh risks — i.e., case-by-case. Cotton was publicly attacked (by LREM MP Coralie Dubost) for sharing this official notice. ▶ 01:01:02
    Sources: Comirnaty SmPC / package leaflet
  • Cotton's report concluded with a formal demand for suspension of the vaccine. The Quebec lawyer who commissioned the report was, ten days after pleading, ordered to undergo a psychiatric evaluation. ▶ 01:02:50
    Sources: Cotton — January 2022 expertise report

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 pediatric clinical study reports (12-15 yrs; 5-11 yrs, Oct 2021) — FDA briefing documents
  • Comirnaty SmPC / package leaflet — EMA EPAR archive / ANSM
  • HAS opinion on Comirnaty (December 2020) — Haute Autorité de Santé
  • Cotton — Expertise report (January 2022) — christinecotton.com
  • Santé publique France preprint (booster effectiveness) — shared on Cotton's Twitter feed
YouTube
"La Commission veut prolonger ce pass sans base scientifique !" Virginie Joron, Christine Cotton
Ligne Droite • La matinale de Radio Courtoisie
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-06-14🎙️ Radio Courtoisie host with Virginie Joron (MEP, Identité et Démocratie)📺 Radio Courtoisie — La matinale (Ligne droite)⏱ 30 min
“If Pfizer had wanted to know who'd had COVID in its trial, they would have done anti-nucleocapsid serology. With that table, you get 56 vaccine cases, not 8 — efficacy is around 56%, not 95%.”

Key statements

  • Joron warns the Commission wants to extend the EU digital COVID certificate to June 2023 with no efficacy study, while the vaccines themselves remain in trial through 2023. ▶ 05:01
    Sources: EU Regulation 2021/953 on the EU Digital COVID Certificate (proposed extension, June 2022)
  • Background: a US federal judge (Mark Pittman) ordered Pfizer to release 55,000 pages of clinical trial documents per month, after the FDA had requested 75 years. The full dataset was scheduled for completion by end-2022. ▶ 09:30
    Sources: PHMPT v. FDA court order (Pittman, Jan 2022)
  • Cotton examined the released SAS data tables — the working files of any biostatistician — rather than the administrative paperwork or filled-in patient case-report forms. ▶ 10:12
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • Had Pfizer wanted to know who'd had COVID in the trial, they would have used anti-nucleocapsid serology. That table exists in the released documents. ▶ 11:38
    Sources: Pfizer C4591001 anti-nucleocapsid serology dataset (court-released)
  • Recomputed on the anti-N serology dataset, the vaccine arm has 56 COVID cases (vs. 162 placebo) — not the 8 vs. 162 used for the headline. Efficacy is closer to 56%, not 95%, and this number was never disclosed by Pfizer in December 2020. ▶ 12:45
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • The trial never studied transmission. In January 2021, when the public was told two doses would restore normal life, Pfizer had no transmission data; later real-world studies were retrofitted to claim a transmission effect. ▶ 14:03
    Sources: Pfizer C4591001 Protocol
  • Five sites recruited nearly 10,000 of the trial's ~38,000 participants — a major imbalance that should have triggered a per-site analysis (it isn't in the reports). One Argentine military hospital alone recruited over 5,000 patients, ramping from 60 to 240 per day. ▶ 19:23
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • Patient IDs in the SAS tables violate the CDISC standard: at the Argentine site (1231), a block of participants is numbered "4444" — an undocumented numbering inconsistent with industry norms. ▶ 20:23
    Sources: Pfizer C4591001 SAS datasets (court-released); CDISC standards
  • Protocol deviations show that vaccine-arm participants who reported COVID-like symptoms were less likely to receive a follow-up PCR visit than placebo-arm participants — confirming the case-detection bias in favor of the vaccine. ▶ 20:42
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • Joron's broader critique: Pfizer effectively decides the validity of its own vaccine; over a million adverse events sit in the EMA database with no formal investigation; the pass sanitaire is a tool to coerce vaccination, not curb transmission. ▶ 22:49
    Sources: EudraVigilance database
  • Joron flags that the Commission has suspended its planned purchase of Valneva (a more conventional protein-based vaccine for the vaccine-hesitant) while sitting on 4 billion mRNA doses with short shelf-lives. ▶ 24:27
    Sources: EU Advance Purchase Agreements (Valneva and Pfizer/BioNTech)
  • The first Pfizer report showed no statistically demonstrated effect on severe forms (too few cases), zero severe cases in adolescents, zero in children. The "prevents severe forms" narrative rests entirely on later real-world studies — most of them methodologically flawed (Cotton flags EPI-PHARE specifically). ▶ 26:53
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020); EPI-PHARE / ANSM real-world studies
  • OPECST (the French parliamentary office for science and technology assessment) published an interim report acknowledging a lack of transparency on adverse events. Cotton testified — but her hearing was not made public. ▶ 28:05
    Sources: OPECST interim report on COVID-19 vaccine adverse events

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 SAS datasets (court-released) — PHMPT v. FDA court order (Pittman, Jan 2022)
  • EU Regulation 2021/953 (EU Digital COVID Certificate) — EUR-Lex
  • EudraVigilance adverse-event database — EMA
  • EU Advance Purchase Agreements (Pfizer/BioNTech, Valneva) — European Commission transparency portal
  • OPECST interim report on COVID-19 vaccine adverse events — Sénat — Office parlementaire d'évaluation des choix scientifiques et technologiques
  • EPI-PHARE / ANSM real-world COVID vaccine studies — epi-phare.fr
YouTube
Autorisation du vaccin COVID : erreurs ou complicités ?
Virginie Joron
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-06-13🎙️ Virginie Joron (MEP, Rassemblement National) — episode 2 of a multi-part series📺 Virginie Joron — YouTube channel⏱ 20 min
“No symptoms, no test, no Covid. We have three and a half times more antipyretic use in the vaccine group. That means I'm suppressing symptoms for three times as many people — so the 95% is wrong.”

Key statements

  • The primary efficacy endpoint — PCR-confirmed symptomatic COVID — is biased because symptom-reporting is participant-driven and antipyretics (paracetamol etc.) were permitted, suppressing symptoms. ▶ 01:46
    Sources: Pfizer C4591001 Protocol
  • Vaccine-group participants took antipyretics 3.5× more often than placebo-group participants. With suppressed symptoms came suppressed testing — and suppressed COVID case counts — artificially inflating the 95% headline. ▶ 02:36
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020) — antipyretic use tables
  • PCR-confirmed symptomatic COVID is not representative of real-world infection. Anti-nucleocapsid serology — which would have caught asymptomatic and undetected cases — was not used to define the endpoint. ▶ 05:05
    Sources: Pfizer C4591001 Protocol
  • Pre-clinical monkey data and Phase 1-2 human data already showed neutralizing antibody decline after two months. In Phase 3, Pfizer performed no antibody titre measurement at three months — the time-point that would have shown waning protection. ▶ 05:39
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
  • Pfizer was already studying a booster dose in December 2020 — the same month it was telling the public a two-dose regimen would restore normal life. They knew protection wouldn't last. ▶ 06:46
    Sources: Pfizer booster sub-study protocol (Dec 2020 amendment to C4591001)
  • GCP guidelines require extreme traceability (every data entry signed, audited server-room access, redundant air conditioning). All of that regulation, designed to protect trial participants and the public, was disregarded in the COVID trials. ▶ 11:11
    Sources: ICH-GCP guidelines
  • The European Commission ordered 4.2 billion doses for 447 million Europeans — roughly 8-9 doses per person. The order itself proves Brussels knew, from the start, that boosters would be needed. ▶ 14:07
    Sources: EU Advance Purchase Agreements (Pfizer/BioNTech)
  • Cotton flags the European Ombudsman's investigation into Ursula von der Leyen's undisclosed SMS messages with Pfizer's CEO Albert Bourla — still unresolved at recording. ▶ 17:32
    Sources: European Ombudsman decision OI/4/2022/PB
  • The Commission awarded McKinsey a 2.5 million euro contract for a 70-page report on "manufacturing options for medical countermeasures against serious cross-border health threats" during the crisis. ▶ 18:06
    Sources: EU Commission–McKinsey contract (2022, medical countermeasures study)
  • Conflict-of-interest pattern: vdL's son works at McKinsey; her husband is a senior officer of a Maastricht-region pharmaceutical company in the Pfizer network. The EU Transparency Register also shows recurring vdL meetings with Bill Gates, Global Citizen, and Open Society. ▶ 18:44
    Sources: EU Transparency Register (vdL meeting log)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer booster sub-study protocol (Dec 2020 amendment to C4591001) — ClinicalTrials.gov registration changes / FDA submission
  • EU Advance Purchase Agreements (Pfizer/BioNTech) — European Ombudsman OI/4/2022/PB; partial redacted versions on European Commission's transparency page
  • European Ombudsman decision OI/4/2022/PB (vdL–Bourla SMS) — ombudsman.europa.eu
  • EU Transparency Register — Commissioner meeting logs — ec.europa.eu/transparencyregister
  • EU Commission–McKinsey contract (medical countermeasures study) — EU Financial Transparency System / TED
YouTube
CeNC - Commission d'enquête nationale citoyenne - bio-statisticienne Christine Cotton témoigne
Actualité Politique Du Québec
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2023-05-30🎙️ Commissioner of the Citizens' National Inquiry Commission (Quebec)📺 Actualité Politique Du Québec — CeNC (Commission d'enquête nationale citoyenne)⏱ 14 min
“The vaccine causes the same symptoms as COVID. So instead of doing a COVID test, doctors blamed the vaccine — no test, no Covid. Vaccine-arm participants took antipyretics more often. The 95% endpoint just measures part of the disease. With anti-N serology, efficacy is around 55%, not 95%.”

Key statements

  • Cotton: 23 years as a biostatistician, founder of a CRO whose clients included AstraZeneca, Pfizer, Sanofi, Bayer, Aventis, and AB Science — covering oncology, CNS, autoimmune, pulmonology, ophthalmology, and more. ▶ 01:08
    Sources: Christine Cotton CV
  • Cotton participated in close to 500 clinical trials over her career — including HCV, tuberculosis, kidney transplant, and diabetes work — establishing the credentialing baseline for her Pfizer critique. ▶ 02:35
    Sources: Christine Cotton CV
  • Drug development normally takes ~15 years from discovery to authorization. The COVID vaccines benefited from accelerated development — each phase starting before the previous one finished, with incomplete results carried forward. ▶ 05:19
    Sources: Pfizer C4591001 Protocol
  • Pregnant or lactating women were never included (standard for protected populations). Immunocompromised patients, those with comorbidities (diabetes, pulmonary disease), and patients with autoimmune or inflammatory conditions were also excluded — i.e., the most fragile populations. ▶ 06:31
    Sources: Pfizer C4591001 Protocol
  • Interaction with other vaccines was not studied; transmission was not studied. Cotton emphasizes the bigger problem is not the (commonly cited) missing transmission data but the way symptomatic cases themselves were measured. ▶ 07:00
    Sources: Pfizer C4591001 Protocol
  • Across every interim analysis (adults, 12-15 yrs, 5-11 yrs, infants), participants had a maximum of three months of follow-up — too short to support any "safe" claim beyond that horizon. ▶ 07:37
    Sources: Pfizer C4591001 interim clinical study reports (adults, 12-15, 5-11, infants)
  • Per the court-released SAS tables (obtained via Aaron Siri's litigation in the US), there were fewer PCR tests in the vaccine arm than the placebo arm — meaning fewer confirmed COVID cases by design, not by protection. ▶ 09:43
    Sources: Pfizer C4591001 SAS datasets (court-released)
  • GCP is a body of regulations, hundreds of documents, governing every task of every actor in a trial. A trial that violates GCP in its endpoint selection or analyses "is worth nothing." ▶ 10:49
    Sources: ICH-GCP guidelines
  • Participants were allowed to take antipyretics — which suppress fever and other COVID-like symptoms. More vaccine-arm participants took them; their symptoms were suppressed, no PCR test was triggered, and the efficacy calculation is biased. ▶ 11:35
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • Anti-nucleocapsid serology — measured but not used as the primary endpoint — gives a fuller picture. Recomputed efficacy on that table is about 55%, not 95%. ▶ 12:17
    Sources: Pfizer C4591001 SAS datasets (court-released)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study reports (adults, 12-15 yrs, 5-11 yrs, infants) — FDA briefing documents and EMA EPAR archive
  • Pfizer C4591001 SAS datasets (court-released) — PHMPT v. FDA litigation (Aaron Siri, ICAN)
  • ICH-GCP guidelines — International Council for Harmonisation
  • Christine Cotton CV — archive/documents/CV_Christine_Cotton_EN.md
No thumbnail
Dailymotion
Les essais cliniques de Pfizer sont-ils frauduleux ? Avec Christine Cotton
Sud Radio
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-02-24🎙️ André Bercoff (host)📺 Sud Radio⏱ 18 min
“The famous 95% in December 2020 is wrong. I can't say if it was 75, 70, 53, 45 — but it is wrong. In 23 years of my career, I've never seen a trial of this mediocrity. When that's the case, you suspend the product.”

Key statements

  • Cotton examined Pfizer's own source documents: the C4591001 protocol, the clinical study reports for the 16+, 12-15, and 5-11 populations, and the EU Risk Management Plan — a document the manufacturer itself prepares for products requiring real-world surveillance. ▶ 01:10
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 clinical study reports; Comirnaty Risk Management Plan
  • The 95% headline of December 2020 is wrong, due to methodological biases that favor the vaccine. Cotton cannot say whether the true figure is 75, 70, 53, or 45 — only that it is not 95. ▶ 02:39
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • The protocol did not schedule an antibody titre measurement at three months post-dose 2 — only at six months. A three-month titre would have shown the waning protection that Pfizer only acknowledged before the CDC in September 2021. ▶ 04:04
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
  • The HAS December 2020 opinion explicitly notes no demonstrated efficacy on transmission. Pfizer was already studying a booster at that same moment — implying they knew protection wouldn't last. ▶ 05:18
    Sources: HAS opinion on Comirnaty (December 2020); Pfizer booster sub-study (Dec 2020 amendment)
  • Maddie de Garay, a participant in the 12-15 trial, suffered 35 adverse events and is now wheelchair-bound with a gastric feeding tube. The clinical study report reduced this to "abdominal pain." ▶ 06:23
    Sources: Pfizer C4591001 pediatric (12-15 yrs) clinical study report
  • Populations excluded from the trial — pregnant women, immunocompromised, comorbid patients, co-administration with other vaccines — are formally flagged in the Risk Management Plan for close real-world monitoring. They were vaccinated anyway. ▶ 07:41
    Sources: Comirnaty Risk Management Plan (December 2020, EMA)
  • In 23 years of clinical-trial work, Cotton says she has never seen a trial of such mediocre quality — GCP violations, methodological biases everywhere — and that this invalidates the headline results. The proper response is to suspend the product. ▶ 08:48
    Sources: ICH-GCP guidelines
  • Cotton refuses to argue real-world efficacy in over-65s on top of biased trial results — GCP exists to prevent exactly this kind of post-hoc reasoning. The ICH framework is designed to minimize the risk of authorizing a product that harms the public. ▶ 10:33
    Sources: ICH-GCP guidelines
  • The Ventavia case (whistleblower Brook Jackson, three centers documented in the BMJ) shows poorly-monitored patient follow-up. With ~150 trial centers, Cotton calls for an independent audit — not one performed by Pfizer itself. ▶ 15:12
    Sources: Ventavia whistleblower case (BMJ, Thacker, November 2021)
  • Cotton submitted her report — alongside the patient-association Verity (which collects adverse-event reports including serious cases up to death) — to France's ANSM and was awaiting a response. ▶ 17:31
    Sources: Cotton — Expertise report (January 2022); Verity association adverse-event collection

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 clinical study reports (16+, 12-15, 5-11) — FDA briefing documents and EMA EPAR archive
  • Comirnaty Risk Management Plan (December 2020) — EMA EPAR archive
  • HAS opinion on Comirnaty (December 2020) — Haute Autorité de Santé
  • Ventavia whistleblower case (Thacker, BMJ 2021) — BMJ 2021;375:n2635
  • Cotton — Expertise report (January 2022) — christinecotton.com
  • ICH-GCP guidelines — International Council for Harmonisation
No thumbnail
Dailymotion
Documents déclassifiés de Pfizer et revelations choc de Christine Cotton
Sud Radio
Transcript: French · English
Watch ▶
In Brief ▾↗ Open as page
📅 2022-05-13🎙️ André Bercoff (host)📺 Sud Radio⏱ 15 min
“Look at real life and stop watching TV, friends. We have hundreds of thousands of adverse events, 25% serious, hitting young people lost in unbelievable medical wandering — 40 trips to the ER without a diagnosis. Lawyers have filed a poisoning complaint.”

Key statements

  • The December 2020 Emergency Use Authorization was based on an interim analysis covering only 3 of the planned 24 months — with half of participants followed less than 2 months. Medium- and long-term tolerance could not be evaluated. ▶ 01:47
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Statistically, no efficacy on severe cases, no efficacy in the over-75s. In adolescents and children, also no demonstrated efficacy on severe forms. The 95% rests on a biased primary endpoint. ▶ 03:19
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • No measurement of neutralizing antibodies at two months post-dose 2 — even though the monkey study and Phase 1-2 data already showed antibody decline from two months out. The omission masked waning protection. ▶ 03:49
    Sources: Pfizer C4591001 Protocol (immunogenicity schedule); Pfizer monkey preclinical study; Pfizer Phase 1-2 results
  • WHO guidance at the time called for six months of follow-up to assess tolerance and one year for efficacy. The three-month interim analysis contravened those prior directives — calling for a halt and an independent audit. ▶ 04:15
    Sources: WHO guidelines on COVID-19 vaccine evaluation (pre-2020)
  • Pfizer's own CEO has acknowledged antibodies decline. A third dose was rolled out, a fourth is in progress, a fifth is arriving in the United States — vaccines do not prevent infection or transmission. The "prevents severe forms" claim rests on real-world studies with questionable methodology. ▶ 04:41
    Sources: Pfizer press statements (Albert Bourla, 2021-2022)
  • Reviewing a Ventavia patient case-report form (PDF) from the released documents, Cotton found a masked COVID date for a patient who apparently died from COVID — indicating non-transparent data handling. ▶ 06:30
    Sources: Pfizer C4591001 case-report forms (court-released, Ventavia site)
  • An Australian biostatistician ("Jikky" / Jikkyleaks) examined the court-released SAS tables and surfaced patient IDs starting with "4444" — outside the CDISC numbering norm. The "4444" block belongs to site 1231, an Argentine military hospital that recruited 5,700+ of the trial's ~44,000 patients between mid-August and end-September 2020. ▶ 09:33
    Sources: Pfizer C4591001 SAS datasets (court-released); CDISC standards
  • Real-world: hundreds of thousands of adverse events with 25% serious — hitting young people now lost in months of medical wandering, sometimes 40 ER visits with no diagnosis, told their symptoms are "all in your head." ▶ 13:49
    Sources: EudraVigilance database; VAERS database
  • Lawyers have taken up the case: a French Senate inquiry into adverse events (where Cotton testified) is under way, and a criminal complaint for "poisoning" by these vaccines has been filed. ▶ 14:34
    Sources: French Senate OPECST inquiry on adverse events; Criminal complaint for poisoning (France)

Documents cited

  • Pfizer C4591001 Protocol — NEJM supplementary materials
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 case-report forms and SAS datasets (court-released) — PHMPT v. FDA litigation
  • Pfizer monkey preclinical study & Phase 1-2 results — Cited in EMA EPAR and peer-reviewed publications (Walsh et al., NEJM 2020)
  • WHO guidelines on COVID-19 vaccine evaluation (pre-2020) — WHO
  • EudraVigilance / VAERS adverse-event databases — EMA / CDC-FDA
  • French Senate OPECST inquiry on COVID-19 vaccine adverse events — Sénat